Cedars-Sinai Medical Center
- Type
- Teaching hospital
- Where
- West Hollywood, CA
- Medicare CCN
- 050625
- Received
- $19,700,147 in 1,287 records, 2024 ($7,141,073 general, $12,559,073 research)
- Source
- CMS Open Payments search ↗
On this site
- Business registration: Cedars-Sinai Medical Center Fuzzy (name and state)
- Business registration: CEDARS-SINAI MEDICAL CENTER Fuzzy (name and state)
- Nonprofit contractor: CEDARS-SINAI MEDICAL CENTER Fuzzy (name and state)
- Plan sponsor: CEDARS-SINAI MEDICAL CENTER Fuzzy (name and state)
- Federal award recipient: CEDARS-SINAI MEDICAL CENTER Fuzzy (name and state)
- Lobbying client: CEDARS-SINAI MEDICAL CENTER Fuzzy (name and state)
- Lobbying client: CEDARS-SINAI MEDICAL CENTER Fuzzy (name and state)
- Lobbying client: CEDARS-SINAI MEDICAL CENTER Fuzzy (name and state)
- Lobbying client: CEDARS-SINAI MEDICAL CENTER Fuzzy (name and state)
- Lobbying registrant: CEDARS-SINAI MEDICAL CENTER Fuzzy (name and state)
- Patent assignee: CEDARS-SINAI MEDICAL CENTER Fuzzy (name and state)
- Trademark owner: Cedars-Sinai Medical Center Fuzzy (name and state)
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2024 | General payment | 377 | $7,141,073 |
| 2024 | Research payment | 910 | $12,559,073 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 910 | $12,559,073 |
| Royalty or License | 13 | $3,626,034 |
| Grant | 145 | $1,882,425 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 22 | $828,029 |
| Space rental or facility fees (teaching hospital only) | 86 | $313,919 |
| Long term medical supply or device loan | 39 | $190,568 |
| Education | 54 | $179,475 |
| Gift | 1 | $42,000 |
| Charitable Contribution | 5 | $28,300 |
| Debt forgiveness | 8 | $25,761 |
| Consulting Fee | 4 | $24,560 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2024-12-31 | Merck Sharp & Dohme LLC | $519,941 | Research payment | In-kind items and services | WELIREG Drug, ONCOLOGY | A Phase 2 Study to Evaluate the Efficacy and Safety of Belzutifan MK-6482, formerly PT2977 Monotherapy in Participants w | 2024 |
| 2024-12-31 | Merck Sharp & Dohme LLC | $397,809 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | An Open-label, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of Pembrolizumab Plus Lenvatinib in Combin | 2024 |
| 2024-12-31 | Merck Sharp & Dohme LLC | $246,042 | Research payment | Cash or cash equivalent | WINREVAIR Biological, CARDIOVASCULAR | A Phase 2, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Effects of Sotatercept versus Placebo for | 2024 |
| 2024-12-31 | Siemens Medical Solutions USA, Inc. | $145,463 | Research payment | In-kind items and services | Eclipse Treatment Planning System for External Beam Radiation Therapy Device, Oncology | Cardiac RADIoablation versus repeat catheter Ablation: a pivotalrandomized clinical Trial Evaluating safety and efficacy | 2024 |
| 2024-12-31 | Merck Sharp & Dohme LLC | $126,071 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | STUDY NAME#Open Label, Phase II Pilot Study of Immune Checkpoint Inhibition with Pembrolizumab in Combination with PARP | 2024 |
| 2024-12-31 | Merck Sharp & Dohme LLC | $101,760 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | An Open-label, Randomized Phase 3 Study to Evaluate Efficacy and Safety of Pembrolizumab MK-3475 in Combination with Bel | 2024 |
| 2024-12-31 | Merck Sharp & Dohme LLC | $97,315 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Clinical Trial of Pembrolizumab MK-3475 Evaluating Predictive Biomarkers in Subjects with Advanced Solid Tumors KEYNOT | 2024 |
| 2024-12-31 | Merck Sharp & Dohme LLC | $23,513 | Research payment | In-kind items and services | WELIREG Drug, ONCOLOGY | An Open-label, Randomized, Phase 3 Study of MK-6482 in Combination with Lenvatinib MK-7902 vs Cabozantinib for Treatment | 2024 |
| 2024-12-31 | Intuitive Surgical, Inc. | $16,840 | Long term medical supply or device loan | In-kind items and services | DAVINCI XI Device, SURGERY | 2024 | |
| 2024-12-31 | Merck Sharp & Dohme LLC | $16,534 | Research payment | In-kind items and services | LENVIMA Drug, ONCOLOGY | A Multicenter, Open-label Phase 2 Study of Lenvatinib E7080,MK-7902 Plus Pembrolizumab MK-3475 in Previously Treated Sub | 2024 |
| 2024-12-31 | Stryker Corporation | $14,947 | Long term medical supply or device loan | In-kind items and services | SPY-PHI System Device, ENDOSCOPY | 2024 | |
| 2024-12-31 | Stryker Corporation | $14,947 | Long term medical supply or device loan | In-kind items and services | SPY-PHI System Device, ENDOSCOPY | 2024 | |
| 2024-12-31 | TAIHO ONCOLOGY, INC. | $13,969 | Research payment | Cash or cash equivalent | Phase 1/2 Open-Label Study of the Safety, Pharmacokinetics, and Preliminary Activity of ASTX295 in Subjects With Wild-Ty | 2024 | |
| 2024-12-31 | Merck Sharp & Dohme LLC | $13,460 | Research payment | In-kind items and services | WELIREG Drug, ONCOLOGY | An Open-label, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of Pembrolizumab Plus Lenvatinib in Combin | 2024 |
| 2024-12-31 | AngioDynamics, Inc. | $13,000 | Long term medical supply or device loan | In-kind items and services | Solero Device, Oncology | 2024 | |
| 2024-12-31 | Merck Sharp & Dohme LLC | $12,879 | Research payment | In-kind items and services | WELIREG Drug, ONCOLOGY | An Open-label, Randomized Phase 3 Study to Evaluate Efficacy and Safety of Pembrolizumab MK-3475 in Combination with Bel | 2024 |
| 2024-12-31 | KARL STORZ Endoscopy-America | $10,886 | Education | In-kind items and services | VITOM Device, MICRO/NOTES/MILITARY | 2024 | |
| 2024-12-31 | Merck Sharp & Dohme LLC | $10,073 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 and Pembrolizumab in Combination wit | 2024 |
| 2024-12-31 | TAIHO ONCOLOGY, INC. | $8,985 | Research payment | Cash or cash equivalent | Phase 1/2 Open-Label Study of the Safety, Pharmacokinetics, and Preliminary Activity of ASTX295 in Subjects With Wild-Ty | 2024 | |
| 2024-12-31 | Merck Sharp & Dohme LLC | $8,834 | Research payment | In-kind items and services | WELIREG Drug, ONCOLOGY | A Phase 2 Study to Evaluate the Efficacy and Safety of Belzutifan MK-6482, formerly PT2977 Monotherapy in Participants w | 2024 |
| 2024-12-31 | Stryker Corporation | $6,347 | Long term medical supply or device loan | In-kind items and services | SPY-PHI System Device, ENDOSCOPY | 2024 | |
| 2024-12-31 | Merck Sharp & Dohme LLC | $6,049 | Research payment | In-kind items and services | WINREVAIR Biological, CARDIOVASCULAR | A Phase 2, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Effects of Sotatercept versus Placebo for | 2024 |
| 2024-12-31 | Stryker Corporation | $5,383 | Long term medical supply or device loan | In-kind items and services | Sabo Device, INSTRUMENTS | 2024 | |
| 2024-12-31 | Intuitive Surgical, Inc. | $5,000 | Education | In-kind items and services | DAVINCI XI Device, SURGERY | 2024 | |
| 2024-12-31 | Intuitive Surgical, Inc. | $5,000 | Education | In-kind items and services | DAVINCI XI Device, SURGERY | 2024 | |
| 2024-12-31 | Stryker Corporation | $4,809 | Debt forgiveness | Cash or cash equivalent | 2024 | ||
| 2024-12-31 | TAIHO ONCOLOGY, INC. | $4,420 | Research payment | Cash or cash equivalent | Phase 1/2 Open-Label Study of the Safety, Pharmacokinetics, and Preliminary Activity of ASTX295 in Subjects With Wild-Ty | 2024 | |
| 2024-12-31 | Stryker Corporation | $4,241 | Long term medical supply or device loan | In-kind items and services | NA Device, INSTRUMENTS | 2024 | |
| 2024-12-31 | Stryker Corporation | $4,087 | Long term medical supply or device loan | In-kind items and services | RemB Device, INSTRUMENTS | 2024 | |
| 2024-12-31 | KARL STORZ Endoscopy-America | $3,235 | Education | In-kind items and services | VITOM Device, MICRO/NOTES/MILITARY | 2024 | |
| 2024-12-31 | Stryker Corporation | $2,790 | Long term medical supply or device loan | In-kind items and services | STRYKER Device, INSTRUMENTS | 2024 | |
| 2024-12-31 | Stryker Corporation | $2,753 | Debt forgiveness | Cash or cash equivalent | 2024 | ||
| 2024-12-31 | Intuitive Surgical, Inc. | $2,720 | Long term medical supply or device loan | In-kind items and services | DAVINCI XI Device, SURGERY | 2024 | |
| 2024-12-31 | Intuitive Surgical, Inc. | $2,720 | Long term medical supply or device loan | In-kind items and services | DAVINCI XI Device, SURGERY | 2024 | |
| 2024-12-31 | Merck Sharp & Dohme LLC | $2,640 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 2, Open-label, Multicenter, Study of an Immunotherapeutic Treatment, DPX-Survivac in combination with Low Dose C | 2024 |
| 2024-12-31 | TAIHO ONCOLOGY, INC. | $2,400 | Research payment | Cash or cash equivalent | Phase 1/2 Open-Label Study of the Safety, Pharmacokinetics, and Preliminary Activity of ASTX295 in Subjects With Wild-Ty | 2024 | |
| 2024-12-31 | KARL STORZ Endoscopy-America | $2,289 | Education | In-kind items and services | VITOM Device, MICRO/NOTES/MILITARY | 2024 | |
| 2024-12-31 | Merck Sharp & Dohme LLC | $2,212 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Double-blind Study to Evaluate Pembrolizumab plus Chemotherapy vs Placebo plus Chemotherapy as | 2024 |
| 2024-12-31 | KARL STORZ Endoscopy-America | $2,079 | Education | In-kind items and services | VITOM Device, MICRO/NOTES/MILITARY | 2024 | |
| 2024-12-31 | Stryker Corporation | $2,071 | Long term medical supply or device loan | In-kind items and services | NA Device, INSTRUMENTS | 2024 | |
| 2024-12-31 | TAIHO ONCOLOGY, INC. | $1,950 | Research payment | Cash or cash equivalent | Phase 1/2 Open-Label Study of the Safety, Pharmacokinetics, and Preliminary Activity of ASTX295 in Subjects With Wild-Ty | 2024 | |
| 2024-12-31 | TAIHO ONCOLOGY, INC. | $1,820 | Research payment | Cash or cash equivalent | Phase 1/2 Open-Label Study of the Safety, Pharmacokinetics, and Preliminary Activity of ASTX295 in Subjects With Wild-Ty | 2024 | |
| 2024-12-31 | Stryker Corporation | $1,658 | Long term medical supply or device loan | In-kind items and services | NA Device, INSTRUMENTS | 2024 | |
| 2024-12-31 | Stryker Corporation | $1,618 | Long term medical supply or device loan | In-kind items and services | NA Device, INSTRUMENTS | 2024 | |
| 2024-12-31 | Stryker Corporation | $1,603 | Long term medical supply or device loan | In-kind items and services | NA Device, INSTRUMENTS | 2024 | |
| 2024-12-31 | Merck Sharp & Dohme LLC | $1,463 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Randomized, Double-Blind, Phase 3 Study of Pemetrexed Platinum Chemotherapy with or without Pembrolizumab MK-3475 in | 2024 |
| 2024-12-31 | Stryker Corporation | $1,307 | Long term medical supply or device loan | In-kind items and services | NA Device, INSTRUMENTS | 2024 | |
| 2024-12-31 | Stryker Corporation | $1,241 | Long term medical supply or device loan | In-kind items and services | NA Device, INSTRUMENTS | 2024 | |
| 2024-12-31 | Stryker Corporation | $1,191 | Long term medical supply or device loan | In-kind items and services | NA Device, INSTRUMENTS | 2024 | |
| 2024-12-31 | Stryker Corporation | $810 | Long term medical supply or device loan | In-kind items and services | STRYKER Device, INSTRUMENTS | 2024 | |
| 2024-12-31 | Stryker Corporation | $802 | Long term medical supply or device loan | In-kind items and services | STRYKER Device, INSTRUMENTS | 2024 | |
| 2024-12-31 | KARL STORZ Endoscopy-America | $643 | Education | In-kind items and services | VITOM Device, MICRO/NOTES/MILITARY | 2024 | |
| 2024-12-31 | Stryker Corporation | $620 | Long term medical supply or device loan | In-kind items and services | NA Device, INSTRUMENTS | 2024 | |
| 2024-12-31 | Merck Sharp & Dohme LLC | $615 | Research payment | In-kind items and services | WELIREG Drug, ONCOLOGY | Open Label Ph III Study of Belzu Zanza 1L post IO in aRCC | 2024 |
| 2024-12-31 | Merck Sharp & Dohme LLC | $560 | Research payment | In-kind items and services | WELIREG Drug, ONCOLOGY | A Phase 3, Randomized, Double-blind, Study of Belzutifan Zanzalintinib Versus Belzutifan Placebo in Participants with | 2024 |
| 2024-12-31 | KARL STORZ Endoscopy-America | $448 | Education | In-kind items and services | VITOM Device, MICRO/NOTES/MILITARY | 2024 | |
| 2024-12-31 | KARL STORZ Endoscopy-America | $394 | Education | In-kind items and services | VITOM Device, MICRO/NOTES/MILITARY | 2024 | |
| 2024-12-31 | AstraZeneca Pharmaceuticals LP | $330 | Research payment | In-kind items and services | A Biomarker-Directed Phase 2 Platform Study in Patients with Advanced Non-Small Cell Lung Cancer whose Disease has Progr | 2024 | |
| 2024-12-31 | AstraZeneca Pharmaceuticals LP | $325 | Research payment | In-kind items and services | LYNPARZA Drug, Oncology | ";A Phase III, Randomised, Double Blind, Placebo Controlled, Multicentre Study of Olaparib Maintenance Monotherapy in Pa | 2024 |
| 2024-12-31 | KARL STORZ Endoscopy-America | $307 | Education | In-kind items and services | VITOM Device, MICRO/NOTES/MILITARY | 2024 | |
| 2024-12-31 | KARL STORZ Endoscopy-America | $218 | Education | In-kind items and services | VITOM Device, MICRO/NOTES/MILITARY | 2024 | |
| 2024-12-31 | Merck Sharp & Dohme LLC | $153 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Double-blind Study to Evaluate Pembrolizumab plus Chemotherapy vs Placebo plus Chemotherapy as | 2024 |
| 2024-12-31 | Stryker Corporation | $110 | Debt forgiveness | Cash or cash equivalent | 2024 | ||
| 2024-12-31 | KARL STORZ Endoscopy-America | $96 | Education | In-kind items and services | VITOM Device, MICRO/NOTES/MILITARY | 2024 | |
| 2024-12-31 | Stryker Corporation | $40 | Debt forgiveness | Cash or cash equivalent | 2024 | ||
| 2024-12-31 | Stryker Corporation | $34 | Debt forgiveness | Cash or cash equivalent | 2024 | ||
| 2024-12-31 | KARL STORZ Endoscopy-America | $22 | Education | In-kind items and services | VITOM Device, MICRO/NOTES/MILITARY | 2024 | |
| 2024-12-31 | KARL STORZ Endoscopy-America | $12 | Education | In-kind items and services | VITOM Device, MICRO/NOTES/MILITARY | 2024 | |
| 2024-12-31 | KARL STORZ Endoscopy-America | $10 | Education | In-kind items and services | VITOM Device, MICRO/NOTES/MILITARY | 2024 | |
| 2024-12-31 | KARL STORZ Endoscopy-America | $9 | Education | In-kind items and services | VITOM Device, MICRO/NOTES/MILITARY | 2024 | |
| 2024-12-30 | ABBVIE INC. | $37,346 | Research payment | Cash or cash equivalent | Study Assessing Activity of Intravenous (IV) ABBV-383 Monotherapy Versus Standard Available Therapies in Adult Participa | 2024 | |
| 2024-12-27 | Boston Scientific Corporation | $22,500 | Grant | Cash or cash equivalent | Device, General - Therapies_ENDO | 2024 | |
| 2024-12-27 | Ethicon Endo-Surgery Inc. | $4,940 | Research payment | Cash or cash equivalent | Echelon; Endopath Device, Endo-Mechanical | A Multi-Center Evaluation of the ECHELONT 3000 (Next Generation Powered Stapler) in Laparoscopic Sleeve Gastrectomy and | 2024 |
| 2024-12-26 | Madrigal Pharmaceuticals | $22,593 | Research payment | Cash or cash equivalent | A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL | 2024 | |
| 2024-12-26 | ABBVIE INC. | $975 | Research payment | Cash or cash equivalent | BOTOX Biological, FACIAL AESTHETICS | Study of BOTOX Injections to Assess Change in Disease Activity and Adverse Events in Adult Female Participants With Inte | 2024 |
| 2024-12-25 | Janssen Biotech, Inc. | $100,000 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2024 | ||
| 2024-12-25 | Blueprint Medicines Corporation | $26,273 | Research payment | Cash or cash equivalent | BLU-945-1101 | 2024 | |
| 2024-12-24 | GT Medical Technologies, Inc | $25,539 | Research payment | Cash or cash equivalent | GammaTile Device, KXK | GTM-102 | 2024 |
| 2024-12-23 | LivaNova USA, Inc. | $8,993 | Debt forgiveness | Cash or cash equivalent | VNS Therapy PerenniaFLEX Model 304 Lead Device, Neurology | 2024 | |
| 2024-12-23 | Regeneron Pharmaceuticals, Inc. | $2,513 | Research payment | Cash or cash equivalent | A DOSE ESCALATION AND PROOF-OF-CONCEPT STUDY OF REGN5459 OR REGN5458 (BCMA x CD3 BISPECIFIC ANTIBODIES) FOR DESENSITIZAT | 2024 | |
| 2024-12-23 | Stryker Corporation | $2,500 | Grant | Cash or cash equivalent | 2024 | ||
| 2024-12-23 | Ethicon Endo-Surgery Inc. | $2,001 | Research payment | Cash or cash equivalent | Echelon; Endopath Device, Endo-Mechanical | A Multi-Center Evaluation of the ECHELONT 3000 (Next Generation Powered Stapler) in Laparoscopic Sleeve Gastrectomy and | 2024 |
| 2024-12-23 | Travere Therapeutics, Inc. | $2,000 | Research payment | Cash or cash equivalent | 021FSGS16010 | 2024 | |
| 2024-12-23 | Travere Therapeutics, Inc. | $1,950 | Research payment | Cash or cash equivalent | 021FSGS16010 | 2024 | |
| 2024-12-23 | Regeneron Pharmaceuticals, Inc. | $1,705 | Research payment | Cash or cash equivalent | A DOSE ESCALATION AND PROOF-OF-CONCEPT STUDY OF REGN5459 OR REGN5458 (BCMA x CD3 BISPECIFIC ANTIBODIES) FOR DESENSITIZAT | 2024 | |
| 2024-12-23 | Travere Therapeutics, Inc. | $1,300 | Research payment | Cash or cash equivalent | 021FSGS16010 | 2024 | |
| 2024-12-23 | Travere Therapeutics, Inc. | $1,092 | Research payment | Cash or cash equivalent | 021FSGS16010 | 2024 | |
| 2024-12-23 | Travere Therapeutics, Inc. | $780 | Research payment | Cash or cash equivalent | 021FSGS16010 | 2024 | |
| 2024-12-23 | KARL STORZ Endoscopy-America | $300 | Charitable Contribution | Cash or cash equivalent | 2024 | ||
| 2024-12-21 | PFIZER INC. | $1,274 | Research payment | Cash or cash equivalent | ELREXFIO Drug, ONCOLOGY | A PHASE 1B2 OPEN LABEL UMBRELLA STUDY OF ELRANATAMAB PF06863135 A BCELL MATURATION ANTIGEN BCMA CD3 BISPECIFIC ANTIBODY | 2024 |
| 2024-12-20 | Synthes GmbH | $12,000 | Grant | Cash or cash equivalent | 2024 | ||
| 2024-12-18 | FUJIFILM Healthcare Americas Corporation | $5,000 | Grant | Cash or cash equivalent | FUJIFILM Device, Medical Device | 2024 | |
| 2024-12-18 | Penumbra, Inc. | $5,000 | Education | Cash or cash equivalent | 2024 | ||
| 2024-12-17 | Boston Scientific Corporation | $343,142 | Grant | In-kind items and services | Device, General - Therapies_ENDO | 2024 | |
| 2024-12-17 | Regeneron Healthcare Solutions, Inc. | $5,950 | Grant | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | 2024 | |
| 2024-12-17 | Takeda Pharmaceuticals U.S.A., Inc. | $546 | Research payment | Cash or cash equivalent | PARADIGHM A NATURAL HISTORY REGISTRY FOR PATIENTS WITH CHRONIC HYPOPARATHYROIDISM | 2024 | |
| 2024-12-16 | Edwards Lifesciences Corporation | $28,729 | Research payment | Cash or cash equivalent | ALLIANCE 2021-05 | 2024 | |
| 2024-12-16 | TAIHO ONCOLOGY, INC. | $5,000 | Education | Cash or cash equivalent | LONSURF Drug, Oncology | 2024 | |
| 2024-12-16 | Medtronic, Inc. | $2,122 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | SMART Trial | 2024 |
| 2024-12-16 | Madrigal Pharmaceuticals | $650 | Research payment | Cash or cash equivalent | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOL | 2024 | |
| 2024-12-13 | PFIZER INC. | $2,210 | Research payment | Cash or cash equivalent | A PHASE 2 RANDOMIZED DOUBLEBLIND DOUBLEDUMMY PLACEBOCONTROLLED DOSERANGING DOSEFINDING PARALLEL GROUP STUDY TO ASSESS EF | 2024 | |
| 2024-12-13 | Smith+Nephew, Inc. | $929 | Research payment | Cash or cash equivalent | TWINFIX Device, Sports Med Shoulder | A Post Market, Prospective Non-Randomized, Multi-Center, Open Label Clinical Evaluation of the Integra TITAN Modular Sho | 2024 |
| 2024-12-13 | Takeda Pharmaceuticals U.S.A., Inc. | $750 | Research payment | Cash or cash equivalent | RELAPSED OR REFRACTORY (R/R) B-CELL NON-HODGKIN LYMPHOMA (NHL) | 2024 | |
| 2024-12-12 | Edwards Lifesciences Corporation | $18,487 | Research payment | Cash or cash equivalent | ALTERRA Post-Approval Study 2021-11 | 2024 | |
| 2024-12-12 | Edwards Lifesciences Corporation | $12,163 | Research payment | Cash or cash equivalent | COMPASSION S3 Post Approval Study (2020-07) | 2024 | |
| 2024-12-12 | Edwards Lifesciences Corporation | $11,822 | Research payment | Cash or cash equivalent | Partner3 2015-08 | 2024 | |
| 2024-12-12 | Edwards Lifesciences Corporation | $7,085 | Research payment | Cash or cash equivalent | ExCEED Trial #2017-18 | 2024 | |
| 2024-12-12 | Penumbra, Inc. | $2,750 | Education | Cash or cash equivalent | 2024 | ||
| 2024-12-12 | Globus Medical, Inc. | $1,839 | Grant | Cash or cash equivalent | 2024 | ||
| 2024-12-12 | Impulse Dynamics (USA) Inc. | $1,332 | Research payment | Cash or cash equivalent | OPTIMIZER Device, Cardiovascular Device | Assessment of CCM in HF With Higher Ejection Fraction (AIM HIGHer) | 2024 |
| 2024-12-12 | Medtronic, Inc. | $500 | Research payment | Cash or cash equivalent | IN.PACT AV Device, Drug-Coated Balloons | PSR-APV | 2024 |
| 2024-12-11 | Medtronic, Inc. | $6,149 | Research payment | Cash or cash equivalent | IN.PACT AV Device, Drug-Coated Balloons | PSR-APV | 2024 |
| 2024-12-11 | Genentech, Inc. | $1,053 | Research payment | Cash or cash equivalent | A Phase 2b efficacy safety trial of Prasinezumab in patients with early Parkinson s Disease | 2024 | |
| 2024-12-10 | Boston Scientific Corporation | $27,020 | Research payment | Cash or cash equivalent | Clinical Trial Product Device, Clinical Trial Product_IC | ACURATE IDE | 2024 |
| 2024-12-10 | ZOLL Medical Corporation | $2,825 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Defibrillator Device, Resuscitation | 2024 | |
| 2024-12-10 | Boston Scientific Corporation | $1,105 | Research payment | Cash or cash equivalent | Clinical Trial Product Device, Clinical Trial Product_PI | ELEGANCE | 2024 |
| 2024-12-10 | Boston Scientific Corporation | $959 | Research payment | Cash or cash equivalent | Clinical Trial Product Device, Clinical Trial Product_IC | AGENT IDE | 2024 |
| 2024-12-09 | Janssen Research & Development, LLC | $32,373 | Research payment | Cash or cash equivalent | A Phase 1 First inhuman Open Label Dose Escalation Study of JNJ61186372 a Human Bispecific EGFR and cMet Antibody in Sub | 2024 | |
| 2024-12-09 | PFIZER INC. | $23,046 | Research payment | Cash or cash equivalent | A PHASE 1 STUDY OF SGNBB228 IN ADVANCED MELANOMA AND OTHER SOLID TUMORS | 2024 | |
| 2024-12-09 | Janssen Research & Development, LLC | $12,230 | Research payment | Cash or cash equivalent | An Open label Phase 11b Study to Evaluate the Safety and Pharmacokinetics of JNJ73841937 Lazertinib a Third Generation E | 2024 | |
| 2024-12-09 | Penumbra, Inc. | $7,133 | Research payment | Cash or cash equivalent | Indigo System Device, Peripheral Intervention | STORM-PE | 2024 |
| 2024-12-09 | Takeda Pharmaceuticals U.S.A., Inc. | $3,250 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | FRUZAQLA Drug, ONCOLOGY | 2024 | |
| 2024-12-09 | Janssen Research & Development, LLC | $1,950 | Research payment | Cash or cash equivalent | A Phase 1 First inhuman Open Label Dose Escalation Study of JNJ61186372 a Human Bispecific EGFR and cMet Antibody in Sub | 2024 | |
| 2024-12-09 | Medtronic, Inc. | $1,501 | Research payment | Cash or cash equivalent | INFUSE BONE GRAFT Device, Bone Matrix/Graft | TLIF IDE Pivotal Study | 2024 |
| 2024-12-09 | Eli Lilly and Company | $210 | Research payment | In-kind items and services | A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE | 2024 | |
| 2024-12-06 | Neurelis, Inc. | $2,500 | Education | Cash or cash equivalent | VALTOCO Drug, EPILEPSY | 2024 | |
| 2024-12-06 | Ascendis Pharma Endocrinology Inc | $259 | Research payment | Cash or cash equivalent | IL Believe | 2024 | |
| 2024-12-05 | E.R. Squibb & Sons, L.L.C. | $80,060 | Royalty or License | Cash or cash equivalent | 2024 | ||
| 2024-12-05 | PFIZER INC. | $29,634 | Research payment | Cash or cash equivalent | ELREXFIO Drug, ONCOLOGY | A PHASE 1B2 OPEN LABEL UMBRELLA STUDY OF ELRANATAMAB PF06863135 A BCELL MATURATION ANTIGEN BCMA CD3 BISPECIFIC ANTIBODY | 2024 |
| 2024-12-05 | Eli Lilly and Company | $18,687 | Research payment | Cash or cash equivalent | 2024 | ||
| 2024-12-05 | TAIHO ONCOLOGY, INC. | $3,250 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | LONSURF Drug, Oncology | 2024 | |
| 2024-12-05 | Edwards Lifesciences Corporation | $3,155 | Research payment | Cash or cash equivalent | ALTERRA Post-Approval Study 2021-11 | 2024 | |
| 2024-12-05 | Genentech USA, Inc. | $2,700 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2024 | ||
| 2024-12-05 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,989 | Research payment | Cash or cash equivalent | BI 1015550 - Ph3 Open Label Extension | 2024 | |
| 2024-12-05 | ABBVIE INC. | $600 | Research payment | Cash or cash equivalent | Flexible-Dose, Adjunctive Therapy Trial in Adults With Parkinson s Disease With Motor Fluctuations (TEMPO-3) | 2024 | |
| 2024-12-04 | Merck Sharp & Dohme LLC | $255,327 | Research payment | Cash or cash equivalent | WELIREG Drug, ONCOLOGY | An Open-label, Randomized Phase 3 Study to Evaluate Efficacy and Safety of Pembrolizumab MK-3475 in Combination with Bel | 2024 |
| 2024-12-04 | ABBVIE INC. | $3,762 | Research payment | Cash or cash equivalent | SKYRIZI Biological, IMMUNOLOGY | A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis | 2024 |
| 2024-12-03 | Eli Lilly and Company | $37,606 | Research payment | Cash or cash equivalent | SUNRAY-01 A GLOBAL PIVOTAL STUDY IN PARTICIPANTS WITH KRAS G12C-MUTANT LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUN | 2024 | |
| 2024-12-03 | ABBVIE INC. | $1,857 | Research payment | Cash or cash equivalent | HUMIRA Biological, IMMUNOLOGY | A Non-Interventional Clinical Study to Evaluate Long-Term Safety and Effectiveness of HUMIRA (Adalimumab) in Pediatric P | 2024 |
| 2024-12-02 | PFIZER INC. | $375,000 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2024 | ||
| 2024-12-02 | Janssen Research & Development, LLC | $15,052 | Research payment | Cash or cash equivalent | ERLEADA Drug, Oncology | A Randomized Double blind Placebo controlled Phase 3 Study of Apalutamide in Subjects with High risk Localized or Locall | 2024 |
| 2024-12-02 | Exelixis Inc. | $5,000 | Charitable Contribution | Cash or cash equivalent | 2024 | ||
| 2024-12-02 | Takeda Pharmaceuticals U.S.A., Inc. | $1,560 | Research payment | Cash or cash equivalent | POST-OP RECOVERY - OREXIN | 2024 | |
| 2024-12-02 | Takeda Pharmaceuticals U.S.A., Inc. | $1,170 | Research payment | Cash or cash equivalent | POST-OP RECOVERY - OREXIN | 2024 | |
| 2024-12-02 | Takeda Pharmaceuticals U.S.A., Inc. | $780 | Research payment | Cash or cash equivalent | POST-OP RECOVERY - OREXIN | 2024 | |
| 2024-12-02 | Takeda Pharmaceuticals U.S.A., Inc. | $650 | Research payment | Cash or cash equivalent | POST-OP RECOVERY - OREXIN | 2024 | |
| 2024-12-02 | Takeda Pharmaceuticals U.S.A., Inc. | $585 | Research payment | Cash or cash equivalent | POST-OP RECOVERY - OREXIN | 2024 | |
| 2024-12-01 | iRhythm Technologies, Inc. | $2,825 | Education | Cash or cash equivalent | ZIO XT Patch Device, Cardiology/Vascular Diseases | 2024 | |
| 2024-11-29 | Medical Device Business Services, Inc. | $10,000 | Grant | Cash or cash equivalent | 2024 | ||
| 2024-11-29 | Eli Lilly and Company | $130 | Research payment | In-kind items and services | A PHASE 3 RANDOMIZED DOUBLE BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WIT | 2024 | |
| 2024-11-29 | Eli Lilly and Company | $130 | Research payment | In-kind items and services | A STUDY OF ORFORGLIPRON (LY3502970) IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH DIET | 2024 | |
| 2024-11-29 | Eli Lilly and Company | $130 | Research payment | In-kind items and services | A PHASE 3 RANDOMIZED DOUBLE BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WIT | 2024 | |
| 2024-11-29 | Eli Lilly and Company | $130 | Research payment | In-kind items and services | A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WIT | 2024 | |
| 2024-11-27 | Merck Sharp & Dohme LLC | $25,682 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 and Pembrolizumab in Combination wit | 2024 |
| 2024-11-27 | Edwards Lifesciences Corporation | $11,393 | Research payment | Cash or cash equivalent | TRISCEND II Pivotal (2020-05) | 2024 | |
| 2024-11-27 | COLOPLAST CORP | $9,230 | Research payment | Cash or cash equivalent | INTIBIA | 2024 | |
| 2024-11-27 | COLOPLAST CORP | $3,407 | Research payment | Cash or cash equivalent | INTIBIA | 2024 | |
| 2024-11-27 | CSL Behring | $2,825 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2024 | ||
| 2024-11-27 | Novocure GmbH | $513 | Research payment | Cash or cash equivalent | EF-32 TRIDENT A Pivotal Randomized, Open -Label Study of Tumor Treating Fields (Optune, 200khz) Concomitant with Radiat | 2024 | |
| 2024-11-26 | DiaSorin Inc. | $67,050 | Research payment | Cash or cash equivalent | MeMed BV Device, Invitro Diagnostics | Assessment and Exploration of LIAISON MeMed BV for Rapid and Precise Differentiation of Bacterial Infections in Emergenc | 2024 |
| 2024-11-26 | Siemens Medical Solutions USA, Inc. | $25,080 | Research payment | Cash or cash equivalent | Cardiac RADIoablation versus repeat catheter Ablation: a pivotal randomized clinical Trial Evaluating safety and efficac | 2024 | |
| 2024-11-26 | PFIZER INC. | $6,329 | Research payment | Cash or cash equivalent | ELREXFIO Drug, ONCOLOGY | A PHASE 1B2 OPEN LABEL UMBRELLA STUDY OF ELRANATAMAB PF06863135 A BCELL MATURATION ANTIGEN BCMA CD3 BISPECIFIC ANTIBODY | 2024 |
| 2024-11-26 | UCB, Inc. | $5,000 | Grant | Cash or cash equivalent | 2024 | ||
| 2024-11-26 | Impulse Dynamics (USA) Inc. | $1,201 | Research payment | Cash or cash equivalent | OPTIMIZER Device, Cardiovascular Device | Post Approval Study (PAS) of the OPTIMIZER Smart and CCM Therapy | 2024 |
| 2024-11-23 | Edwards Lifesciences Corporation | $93,629 | Research payment | Cash or cash equivalent | The PROGRESS Trial – Continued Access 2021-01-CAP | 2024 | |
| 2024-11-23 | Edwards Lifesciences Corporation | $2,210 | Research payment | Cash or cash equivalent | CLASP IID 2018-07 | 2024 | |
| 2024-11-22 | AstraZeneca Pharmaceuticals LP | $3,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | TAGRISSO Drug, Oncology | 2024 | |
| 2024-11-22 | ABBVIE INC. | $2,500 | Grant | Cash or cash equivalent | DUOPA Drug, NEUROSCIENCE | 2024 | |
| 2024-11-22 | W. L. Gore & Associates, Inc. | $1,664 | Research payment | Cash or cash equivalent | Product in Development Device, Devices | Evaluation of the GORE Ascending Stent Graft in the Treatment of Isolated Lesions, Pseudoaneurysms, and Penetrating Aort | 2024 |
| 2024-11-21 | Novocure Inc. | $9,910 | Research payment | Cash or cash equivalent | EF-27 Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields, 150kHz) concomitant with gemcitabine and | 2024 | |
| 2024-11-21 | Novocure Inc. | $2,730 | Research payment | Cash or cash equivalent | EF-27 Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields, 150kHz) concomitant with gemcitabine and | 2024 | |
| 2024-11-21 | TAIHO ONCOLOGY, INC. | $1,950 | Research payment | Cash or cash equivalent | Phase 1/2 Open-Label Study of the Safety, Pharmacokinetics, and Preliminary Activity of ASTX295 in Subjects With Wild-Ty | 2024 | |
| 2024-11-21 | PFIZER INC. | $500 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2024 |
| 2024-11-21 | PFIZER INC. | $500 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2024 |
| 2024-11-21 | PFIZER INC. | $500 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2024 |
| 2024-11-21 | PFIZER INC. | $500 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2024 |
| 2024-11-20 | Arthrex, Inc. | $10,000 | Research payment | Cash or cash equivalent | 2024 | ||
| 2024-11-20 | TAIHO ONCOLOGY, INC. | $8,985 | Research payment | Cash or cash equivalent | Phase 1/2 Open-Label Study of the Safety, Pharmacokinetics, and Preliminary Activity of ASTX295 in Subjects With Wild-Ty | 2024 | |
| 2024-11-20 | TAIHO ONCOLOGY, INC. | $4,420 | Research payment | Cash or cash equivalent | Phase 1/2 Open-Label Study of the Safety, Pharmacokinetics, and Preliminary Activity of ASTX295 in Subjects With Wild-Ty | 2024 | |
| 2024-11-20 | UCB, Inc. | $2,500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2024 | ||
| 2024-11-20 | TAIHO ONCOLOGY, INC. | $1,820 | Research payment | Cash or cash equivalent | Phase 1/2 Open-Label Study of the Safety, Pharmacokinetics, and Preliminary Activity of ASTX295 in Subjects With Wild-Ty | 2024 | |
| 2024-11-19 | Boston Scientific Corporation | $25,122 | Research payment | Cash or cash equivalent | Clinical Trial Product Device, Clinical Trial Product_IC | ACURATE IDE | 2024 |
| 2024-11-18 | PFIZER INC. | $40,191 | Research payment | Cash or cash equivalent | AN OPEN LABEL PHASE 2 BASKET STUDY OF SEA CD40 COMBINATION THERAPIES IN ADVANCED MALIGNANCIES | 2024 | |
| 2024-11-18 | Abbott Laboratories | $11,056 | Research payment | Cash or cash equivalent | AGILIS Device, ELECTROPHYSIOLOGY | VOLT-AF IDE Clinical Study | 2024 |
| 2024-11-18 | Gilead Sciences, Inc. | $8,250 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Trodelvy Drug, ONC | 2024 | |
| 2024-11-18 | Medtronic, Inc. | $4,745 | Research payment | Cash or cash equivalent | HARMONY Device, Heart Valves | Harmony PAS2 | 2024 |
| 2024-11-18 | Abbott Laboratories | $2,319 | Research payment | Cash or cash equivalent | PORTICO Device, STRUCTURAL HEART | Evaluation of the Portico NG (Next Generation) Transcatheter Aortic Valve in High and Extreme Risk Patients With Symptom | 2024 |
| 2024-11-18 | Abbott Laboratories | $352 | Research payment | Cash or cash equivalent | JETI ALL IN ONE NON-STERILE KIT Device, VASCULAR | JET Enhanced Thrombectomy Intervention Registry - JETi Registry | 2024 |
| 2024-11-18 | Abbott Laboratories | $68 | Research payment | Cash or cash equivalent | PORTICO Device, STRUCTURAL HEART | Portico Re-sheathable Transcatheter Aortic Valve System US IDE Trial (PORTICO-IDE) | 2024 |
| 2024-11-15 | Iovance Biotherapeutics, Inc. | $3,461 | Research payment | Cash or cash equivalent | Proleukin Drug, Oncology | NCT05361174 | 2024 |
| 2024-11-15 | Madrigal Pharmaceuticals | $3,014 | Research payment | Cash or cash equivalent | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOL | 2024 | |
| 2024-11-15 | PharmaEssentia USA Corporation | $3,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | BESREMI Drug, Oncology | 2024 | |
| 2024-11-15 | Merck Sharp & Dohme LLC | $3,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | 2024 | |
| 2024-11-15 | Merck Sharp & Dohme LLC | $3,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | 2024 | |
| 2024-11-15 | PROGENICS PHARMACEUTICALS, INC. | $3,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | PYLARIFY Drug, RADIOPHARMACEUTICAL | 2024 | |
| 2024-11-15 | Astellas Pharma US Inc | $3,000 | Grant | Cash or cash equivalent | Xospata Drug, Oncology | 2024 | |
| 2024-11-15 | Iovance Biotherapeutics, Inc. | $1,080 | Research payment | Cash or cash equivalent | Proleukin Drug, Oncology | NCT05361174 | 2024 |
| 2024-11-14 | ARRAY BIOPHARMA INC | $2,950 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2024 | ||
| 2024-11-13 | VERTEX PHARMACEUTICALS INCORPORATED | $412,500 | Research payment | Cash or cash equivalent | Patient-derived pancreas-on-a-chip to study cystic fibrosis-related diabetes | 2024 | |
| 2024-11-13 | PFIZER INC. | $29,713 | Research payment | Cash or cash equivalent | A PHASE 2 RANDOMIZED DOUBLEBLIND DOUBLEDUMMY PLACEBOCONTROLLED DOSERANGING DOSEFINDING PARALLEL GROUP STUDY TO ASSESS EF | 2024 |
The latest 200 records of 1,287.
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In West Hollywood, CA, county Los Angeles County, CA, state California; placed by its city name.
| Measure | Place (city or town) West Hollywood, CA | County Los Angeles County, CA | State California |
|---|---|---|---|
| Population B01003 | 34,884 | 9,808,667 | 39,287,377 |
| Population, 2020 census P1 | 35,757 | 10,014,009 | 39,538,223 |
| Median age B01002 | 40.0 | 38.2 | 37.9 |
| Under 18 B01001 | 3.6% | 20.6% | 22.0% |
| 65 and over B01001 | 16.8% | 15.2% | 15.7% |
| Households B11001 | 22,920 | 3,416,449 | 13,548,091 |
| Foreign born B05002 | 23.6% | 33.4% | 27.0% |
| Median household income B19013 | $96,995 | $90,112 | $99,122 |
| Median family income B19113 | $126,364 | $101,573 | $113,346 |
| Per capita income B19301 | $90,080 | $45,792 | $49,513 |
| Poverty rate B17001 | 12.9% | 13.7% | 12.0% |
| Unemployment rate B23025 | 8.9% | 7.3% | 6.6% |
| Civilian labor force B23025 | 25,818 | 5,200,656 | 20,068,466 |
| Mean commute (minutes) B08013 | 27.1 | 30.4 | 28.7 |
| Bachelor's degree or higher B15003 | 64.2% | 36.0% | 37.1% |
| Housing units B25001 | 26,079 | 3,650,466 | 14,644,735 |
| Owner-occupied B25003 | 19.8% | 45.9% | 55.9% |
| Renters B25003 | 80.2% | 54.1% | 44.1% |
| Median home value B25077 | $924,800 | $834,200 | $734,700 |
| Median gross rent B25064 | $2,091 | $1,954 | $2,036 |
| White, not Hispanic B03002 | 69.5% | 24.7% | 33.8% |
| Black B03002 | 4.3% | 7.4% | 5.2% |
| Hispanic or Latino B03002 | 13.1% | 48.4% | 40.2% |
| Asian B03002 | 6.1% | 14.9% | 15.3% |
| American Indian and Alaska Native B03002 | 0.1% | 0.2% | 0.3% |
Economy now FRED unemployment 5.1% in Sep 2026 (5.5% a year earlier); per capita personal income $90,957 in 2025, up 30% in five years (+4.3% after inflation); the state; Source: FRED, Federal Reserve Bank of St. Louis.
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in West Hollywood, CA.
Comments